Anticancer properties of distinct antimalarial drug classes

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Van Huijsduijnen, Rob Hooft ^a   Guy, R Kiplin ^b   Chibale, Kelly ^c   Haynes, Richard K ^d   Peitz, Ingmar ^e   Kelter, Gerhard ^e   Phillips, Margaret A ^f   Vennerstrom, Jonathan L ^g   Yuthavong, Yongyuth ^h   Wells, Timothy N C ^a  

^a Medicines for Malaria Venture MMV   (Switzerland)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d NORTH WEST UNIVERSITY   (South Africa)

^e CHARLES RIVER LABORATORIES   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

^g NEBRASKA MEDICAL CENTER   (United States)

^h NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIALS; ANTINEOPLASTIC AGENTS; ARTEMISININS; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FOLIC ACID ANTAGONISTS; GENE EXPRESSION; HUMANS; PEROXIDES;

EID: 84894252057     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082962     Document Type: Article

References (105)

1. Krishna S, Bustamante L, Haynes RK, Staines HM (2008) Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 29: 520-527.
2. Zhang CZ, Pan Y, Cao Y, Lai PB, Liu L, et al. (2012) Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo. PLoS One 7: e39870.
3. Tin AS, Sundar SN, Tran KQ, Park AH, Poindexter KM, et al. (2012) Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. Anticancer Drugs 23: 370-379.
4. Wang Z, Yu Y, Ma J, Zhang H, Zhang H, et al. (2012) LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics. Mol Pharm 9: 2646-2657.
5. Zhang CZ, Zhang H, Yun J, Chen GG, Lai PB (2012) Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol 83: 1278-1289.
6. Soomro S, Langenberg T, Mahringer A, Konkimalla VB, Horwedel C, et al. (2011) Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties. J Cell Mol Med 15: 1122-1135.
7. Gao N, Budhraja A, Cheng S, Liu EH, Huang C, et al. (2011) Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo. Apoptosis 16: 511-523.
8. Noori S, Hassan ZM (2011) Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo. Cell Immunol 271: 67-72.
9. Singh NP, Lai HC, Park JS, Gerhardt TE, Kim BJ, et al. (2011) Effects of artemisinin dimers on rat breast cancer cells in vitro and in vivo. Anticancer Res 31: 4111-4114.
10. Weifeng T, Feng S, Xiangji L, Changqing S, Zhiquan Q, et al. (2011) Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells. Phytomedicine 18: 158-162.
11. Zhao Y, Jiang W, Li B, Yao Q, Dong J, et al. (2011) Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2/M phase. Int Immunopharmacol 11: 2039-2046.
12. Xu Q, Li ZX, Peng HQ, Sun ZW, Cheng RL, et al. (2011) Artesunate inhibits growth and induces apoptosis in human osteosarcoma HOS cell line in vitro and in vivo. J Zhejiang Univ Sci B 12: 247-255.
13. Crespo-Ortiz MP, Wei MQ (2012) Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol 2012: 247597.
14. Zhang ZY, Yu SQ, Miao LY, Huang XY, Zhang XP, et al. (2008) [Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial]. Zhong Xi Yi Jie He Xue Bao 6: 134-138.
15. Singh NP, Panwar VK (2006) Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther 5: 391-394. (Pubitemid 44722000)
16. Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, et al. (2005) Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol Rep 14: 1599-1603.
17. Panossian LA, Garga NI, Pelletier D (2005) Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Ann Neurol 58: 812-813. (Pubitemid 41552563)
18. Singh NP, Verma KB (2002) Case report of a laryngeal squamous cell carcinoma treated with artesunate. Archive of Oncology 10: 279-280. (Pubitemid 36164142)
19. Rowen RJ (2002) Chinese Herb Cures Cancer. Second Opinion XII.
20. White CL (2002) Cancer Smart Bomb, Part I: An Idea from Ancient Chinese Medicine. Excerpted from New Horizons, Summer 2002 issue Brewer Science Library.
21. Li Q, Weina P, Hickma M (2013) The Use of Artemisinin Compounds as Angiogenesis Inhibitors to Treat Cancer. In: Chai J, editor. Research Directions in Tumor Angiogenesis.
22. Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Mayanja-Kizza H, et al. (2012) Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults. Malar J 11: 132.
23. Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul W, et al. (2006) The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Eur J Clin Pharmacol 62: 1003-1009. (Pubitemid 44786491)
24. Khanh NX, de Vries PJ, Ha LD, van Boxtel CJ, Koopmans R, et al. (1999) Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for Falciparum malaria. Antimicrob Agents Chemother 43: 690-692. (Pubitemid 29109543)
25. Ashton M, Hai TN, Sy ND, Huong DX, Van Huong N, et al. (1998) Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos 26: 25-27. (Pubitemid 28071320)
26. Hien TT, White NJ (1993) Qinghaosu. Lancet 341: 603-608. (Pubitemid 23066156)
27. Zhang S, Gerhard GS (2008) Heme activates artemisinin more efficiently than hemin, inorganic iron, or hemoglobin. Bioorg Med Chem 16: 7853-7861.
28. Meshnick SR, Thomas A, Ranz A, Xu CM, Pan HZ (1991) Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. Mol Biochem Parasitol 49: 181-189.
29. O'Neill PM, Barton VE, Ward SA (2010) The molecular mechanism of action of artemisinin-the debate continues. Molecules 15: 1705-1721.
30. Noori S, Hassan ZM, Taghikhani M, Rezaei B, Habibi Z (2010) Dihydroartemisinin can inhibit calmodulin, calmodulin-dependent phosphodiesterase activity and stimulate cellular immune responses. Int Immunopharmacol 10: 213-217.
31. Chen X, Lin H, Wen J, Rong Q, Xu W, et al. (2012) Dihydroartemisinin suppresses cell proliferation, invasion, and angiogenesis in human glioma U87 cells. African Journal of Pharmacy and Pharmacology 6: 2433-2440.
32. Eichhorn T, Schloissnig S, Hahn B, Wendler A, Mertens R, et al. (2012) Bioinformatic and experimental fishing for artemisinin-interacting proteins from human nasopharyngeal cancer cells. Mol Biosyst 8: 1311-1318.
33. Chen H, Shi L, Yang X, Li S, Guo X, et al. (2010) Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells. Int J Hematol 92: 587-597.
34. Zhou HJ, Wang WQ, Wu GD, Lee J, Li A (2007) Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol 47: 131-138. (Pubitemid 47095451)
35. Wang J, Guo Y, Zhang BC, Chen ZT, Gao JF (2007) Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial cells. Pharmacology 80: 207-218. (Pubitemid 47557254)
36. Chen HH, Zhou HJ, Wu GD, Lou XE (2004) Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology 71: 1-9.
37. Huan-huan C, Li-Li Y, Shang-Bin L (2004) Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell. Cancer Lett 211: 163-173. (Pubitemid 38824630)
38. Zhou C, Pan W, Wang XP, Chen TS (2012) Artesunate induces apoptosis via a Bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells. J Cell Physiol 227: 3778-3786.
39. Handrick R, Ontikatze T, Bauer KD, Freier F, Rubel A, et al. (2010) Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol Cancer Ther 9: 2497-2510.
40. Kim SJ, Kim MS, Lee JW, Lee CH, Yoo H, et al. (2006) Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. J Cancer Res Clin Oncol 132: 129-135.
41. Singh NP, Lai HC (2004) Artemisinin induces apoptosis in human cancer cells. Anticancer Res 24: 2277-2280. (Pubitemid 39166306)
42. Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, et al. (2004) Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 37: 998-1009. (Pubitemid 39164582)
43. Sadava D, Phillips T, Lin C, Kane SE (2002) Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett 179: 151-156. (Pubitemid 34215106)
44. Lai H, Singh NP (1995) Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 91: 41-46.
45. Daniels TR, Delgado T, Helguera G, Penichet ML (2006) The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121: 159-176. (Pubitemid 44572972)
46. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML (2006) The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121: 144-158. (Pubitemid 44592578)
47. Zeng QP, Zhang PZ (2011) Artesunate mitigates proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase. Nitric Oxide 24: 110-112.
48. Zhang S, Gerhard GS (2009) Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. PLoS One 4: e7472.
49. Li W, Mo W, Shen D, Sun L, Wang J, et al. (2005) Yeast model uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet 1: e36.
50. Huang XJ, Li CT, Zhang WP, Lu YB, Fang SH, et al. (2008) Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells. Pharmacology 82: 1-9.
51. Efferth T, Giaisi M, Merling A, Krammer PH, Li-Weber M (2007) Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One 2: e693.
52. Kong R, Jia G, Cheng ZX, Wang YW, Mu M, et al. (2012) Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. PLoS One 7: e37222.
53. Lu JJ, Chen SM, Ding J, Meng LH (2012) Characterization of dihydroarte-misinin-resistant colon carcinoma HCT116/R cell line. Mol Cell Biochem 360: 329-337.
54. Efferth T, Herrmann F, Tahrani A, Wink M (2011) Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin. Phytomedicine 18: 959-969.
55. Anfosso L, Efferth T, Albini A, Pfeffer U (2006) Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J 6: 269-278. (Pubitemid 44137954)
56. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR (2001) The anti-malarial artesunate is also active against cancer. Int J Oncol 18: 767-773.
57. Haynes RK, Fugmann B, Stetter J, Rieckmann K, Heilmann HD, et al. (2006) Artemisone-a highly active antimalarial drug of the artemisinin class. Angew Chem Int Ed Engl 45: 2082-2088. (Pubitemid 44105182)
58. Giammarioli AM, Maselli A, Casagrande A, Gambardella L, Gallina A, et al. (2008) Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism. Cancer Res 68: 5291-5300.
59. Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, et al. (2012) Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A 109: 16823-16828.
60. Coteron JM, Marco M, Esquivias J, Deng X, White KL, et al. (2011) Structu-reguided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J Med Chem 54: 5540-5561.
61. Roth T, Burger AM, Dengler W, Willmann H, Fiebig HH (1999) Human tumor cell lines demonstrating the characteristics of patient tumors as useful models for anticancer drug screening. In: Fiebig HH, Burger AM, editors. Relevance of Tumor Models for Anticancer Drug Development, Contrib Oncol pp. 145-156.
62. Fiebig HH, Winterhalter B, Berger DP, Lohr GW (1989) Combined in vitro/in vivo test procedure with human tumor xenografts for anticancer drug development. Strahlenther Onkol 165: 522-524. (Pubitemid 19179958)
63. Fiebig HH, Dengler WA, Roth T (1999) Human tumor xenografts: Predictivity, characterization, and discovery of new anticancer agents. In: Fiebig HH, Burger AM, editors. Relevance of Tumor Models for Anticancer Drug Development Contrib Oncol. pp. 29-50.
64. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
65. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, et al. (2001) Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 98: 8012-8017. (Pubitemid 32642678)
66. Dirks WG, Faehnrich S, Estella IA, Drexler HG (2005) Short tandem repeat DNA typing provides an international reference standard for authentication of human cell lines. ALTEX 22: 103-109. (Pubitemid 40974880)
67. Dengler WA, Schulte J, Berger DP, Mertelsmann R, Fiebig HH (1995) Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Anticancer Drugs 6: 522-532.
68. Chou TC (1991) The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout DC, editors. Synergism and antagonism in chemotherapy. San Diego: Academic Press. pp. 61-102.
69. Chou TC, Hayball MP (1996) CalcuSyn for Windows. Software for Dose Effect Analysis. Cambridge: Biosoft Copyright 1996-2005 (CalcuSyn 2).
70. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, et al. (2004) Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430: 900-904. (Pubitemid 39119218)
71. Younis Y, Douelle F, Feng TS, Gonzalez Cabrera D, Le Manach C, et al. (2012) 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem 55: 3479-3487.
72. Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, et al. (2011) Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A 108: 4400-4405.
73. Zhou L, Alker A, Ruf A, Wang X, Chiu FC, et al. (2008) Characterization of the two major CYP450 metabolites of ozonide (1,2,4-trioxolane) OZ277. Bioorg Med Chem Lett 18: 1555-1558. (Pubitemid 351318262)
74. Kaiser M, Wittlin S, Nehrbass-Stuedli A, Dong Y, Wang X, et al. (2007) Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160). Antimicrob Agents Chemother 51: 2991-2993. (Pubitemid 47206243)
75. Ramharter M, Burkhardt D, Nemeth J, Adegnika AA, Kremsner PG (2006) In vitro activity of artemisone compared with artesunate against Plasmodium falciparum. Am J Trop Med Hyg 75: 637-639. (Pubitemid 46941267)
76. Wang X, Dong Y, Wittlin S, Charman SA, Chiu FC, et al. (2013) Comparative Antimalarial Activities and ADME Profiles of Ozonides (1,2,4-trioxolanes) OZ277, OZ439, and Their 1,2-Dioxolane, 1,2,4-Trioxane, and 1,2,4,5-Tetraoxane Isosteres. J Med Chem.
77. Mielgo A, Torres VA, Clair K, Barbero S, Stupack DG (2009) Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules. Oncogene 28: 3551-3562.
78. Wagner HP, Swidzinska PM, Hirt A (1977) Variable duration of vincristine-induced metaphase block in leukemic and nornal bone marrow cells of children. Med Pediatr Oncol 3: 75-83. (Pubitemid 8053023)
79. Chen H, Sun B, Wang S, Pan S, Gao Y, et al. (2010) Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. J Cancer Res Clin Oncol 136: 897-903.
80. Chen Y, Choong LY, Lin Q, Philp R, Wong CH, et al. (2007) Differential expression of novel tyrosine kinase substrates during breast cancer development. Mol Cell Proteomics 6: 2072-2087.
81. Lim S, Green JA, Wong H, VanderBurg ME, Crook T (2007) DUSP7 and DUSP8 promoter hypermethylations: Predictors of clinical outcomes in advanced epithelial ovarian carcinoma. Journal of Clinical Oncology 25: 5501.
82. Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, et al. (2010) p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 70: 832-841.
83. Perneger TV (1998) What's wrong with Bonferroni adjustments. BMJ 316: 1236-1238.
84. Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM, Pascual-Montano A (2007) GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol 8: R3.
85. Sertel S, Eichhorn T, Simon CH, Plinkert PK, Johnson SW, et al. (2010) Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. Molecules 15: 2886-2910.
86. Zhang X, Liang D, Guo B, Deng W, Chi ZH, et al. (2013) Zinc transporter 5 and zinc transporter 7 induced by high glucose protects peritoneal mesothelial cells from undergoing apoptosis. Cell Signal 25: 999-1010.
87. Ryu MS, Guthrie GJ, Maki AB, Aydemir TB, Cousins RJ (2012) Proteomic analysis shows the upregulation of erythrocyte dematin in zinc-restricted human subjects. Am J Clin Nutr 95: 1096-1102.
88. Iyengar V, Pullakhandam R, Nair KM (2012) Coordinate expression and localization of iron and zinc transporters explain iron-zinc interactions during uptake in Caco-2 cells: implications for iron uptake at the enterocyte. J Nutr Biochem 23: 1146-1154.
89. Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, et al. (2008) Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol Ther 7: 1017-1023.
90. Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, et al. (2007) Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS One 2: e798.
91. Huang XJ, Ma ZQ, Zhang WP, Lu YB, Wei EQ (2007) Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. J Pharm Pharmacol 59: 849-856.
92. Zhou HJ, Wang Z, Li A (2008) Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression. Anticancer Drugs 19: 247-255.
93. Hu Z, Hung JH, Wang Y, Chang YC, Huang CL, et al. (2009) VisANT 3.5: multi-scale network visualization, analysis and inference based on the gene ontology. Nucleic Acids Res 37: W115-121.
94. Hu Z, Mellor J, Wu J, DeLisi C (2004) VisANT: an online visualization and analysis tool for biological interaction data. BMC Bioinformatics 5: 17.
95. Cody R, Stewart D, DeForni M, Moore M, Dallaire B, et al. (1993) Multicenter phase II study of brequinar sodium in patients with advanced breast cancer. Am J Clin Oncol 16: 526-528.
96. Dondorp A, Nosten F, Stepniewska K, Day N, White N, et al. (2005) Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366: 717-725. (Pubitemid 41207233)
97. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, et al. (2010) Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376: 1647-1657.
98. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, et al. (2011) Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J 10: 263.
99. Moehrle JJ, Duparc S, Siethoff C, van Giersbergen PL, Craft JC, et al. (2012) First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol.
100. Jacobson JM, Davidian M, Rainey PM, Hafner R, Raasch RH, et al. (1996) Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. Antimicrob Agents Chemother 40: 1360-1365. (Pubitemid 26000564)
101. Valecha N, Looareesuwan S, Martensson A, Abdulla SM, Krudsood S, et al. (2010) Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. Clin Infect Dis 51: 684-691.
102. Nagelschmitz J, Voith B, Wensing G, Roemer A, Fugmann B, et al. (2008) First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob Agents Chemother 52: 3085-3091.
103. Green MD, van Eijk AM, van Ter Kuile FO, Ayisi JG, Parise ME, et al. (2007) Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J Infect Dis 196: 1403-1408. (Pubitemid 351412014)
104. Karunajeewa HA, Salman S, Mueller I, Baiwog F, Gomorrai S, et al. (2009) Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Antimicrob Agents Chemother 53: 4368-4376.
105. Mansor SM, Navaratnam V, Mohamad M, Hussein S, Kumar A, et al. (1989) Single dose kinetic study of the triple combination mefloquine/sulphadoxine/ pyrimethamine (Fansimef) in healthy male volunteers. Br J Clin Pharmacol 27: 381-386. (Pubitemid 19097451)